News & Media
Press Releases
2023
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
December 12, 2023
2022
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
April 27, 2022
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
April 20, 2022
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
January 31, 2022
2020
Obiltoxaximab receives marketing authorization from European Commission for the treatment of Inhalation Anthrax
December 2, 2020
Obiltoxaximab receives positive CHMP opinion for the treatment of Inhalation Anthrax
October 8, 2020
Elusys Therapeutics receives Health Canada approval for Anthim® for the treatment for Inhalation Anthrax
August 12, 2020